[In vitro antibacterial activity of ciprofloxacin against uropathogenic organisms].
Ciprofloxacin (Bay 09867) is a new quinoline derivative. Its activity against 537 urinary bacterial isolates was compared with those of ampicillin, amikacin, carbenicillin, cefazolin, cefotaxime, cefoxitin, ceftazidime, nalidixic and oxolinic acids, norfloxacin, trimethoprim, and other antimicrobial agents, when appropriate. It inhibited 90% Citrobacter freundii, Enterobacter spp., E, coli, Klebsiella spp., Proteus spp., and Serratia spp. at less than or equal to 0.78 microgram/ml. The majority of Pseudomonas aeruginosa, including gentamicin-resistant strains, was inhibited by less than or equal to 3.12 micrograms/ml. MICs of Bay 09867 for 90% of Staphylococcus aureus, including methicillin-resistant strains, and Streptococcus faecalis were 0.78 micrograms/ml and 1.56 micrograms/ml respectively. Bay 09867 inhibited organisms resistant to ampicillin, carbenicillin, cefazolin, nalidixic and oxolinic acids and trimethoprim.
D000892:Anti-Infective Agents, Urinary; D002939:Ciprofloxacin; D004755:Enterobacteriaceae / Q000187:drug effects; D013293:Enterococcus faecalis / Q000187:drug effects; D008826:Microbial Sensitivity Tests; D011550:Pseudomonas aeruginosa / Q000187:drug effects; D011804:Quinolines / Q000494:pharmacology*; D013211:Staphylococcus aureus / Q000187:drug effects
D000892:Anti-Infective Agents, Urinary; D011804:Quinolines; D002939:Ciprofloxacin
Attivita' antibatterica "in vitro" della ciprofloxacina nei confronti di germi uropatogeni.